Compare BTDR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | RARE |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2021 | 2013 |
| Metric | BTDR | RARE |
|---|---|---|
| Price | $11.42 | $26.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 20 |
| Target Price | $22.70 | ★ $59.10 |
| AVG Volume (30 Days) | ★ 8.6M | 2.7M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $72.51 | $13.12 |
| Revenue Next Year | $40.84 | $37.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $7.04 | $18.29 |
| 52 Week High | $27.80 | $39.89 |
| Indicator | BTDR | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 36.47 |
| Support Level | $10.09 | $21.54 |
| Resistance Level | $12.86 | $27.42 |
| Average True Range (ATR) | 1.11 | 1.54 |
| MACD | -0.06 | -1.00 |
| Stochastic Oscillator | 29.33 | 0.74 |
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.